PA
AKRO

Parallel Advisors’s Akero Therapeutics AKRO Stock Holding History

Parallel Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,166
Closed -$55.4K – 3625
2025
Q3 		$55.4K Sell
1,166
-4,000
-77% -$194K ﹤0.01% 1730
2025
Q2 		$276K Sell
5,166
-3
-0.1% -$136 0.01% 865
2025
Q1 		$219K Sell
5,169
-370
-7% -$15.7K ﹤0.01% 921
2024
Q4 		$154K Buy
5,539
+3
+0.1% +$91 ﹤0.01% 1057
2024
Q3 		$159K Hold
5,536
– – ﹤0.01% 1026
2024
Q2 		$130K Buy
5,536
+26
+0.5% +$556 ﹤0.01% 1058
2024
Q1 		$139K Sell
5,510
-76
-1% -$1.82K ﹤0.01% 1023
2023
Q4 		$130K Buy
5,586
+76
+1% +$1.5K ﹤0.01% 1002
2023
Q3 		$279K Hold
5,510
– – 0.01% 650
2023
Q2 		$257K Sell
5,510
-250
-4% -$11.5K 0.01% 678
2023
Q1 		$220K Sell
5,760
-23
-0.4% -$1.02K 0.01% 724
2022
Q4 		$317K Sell
5,783
-250
-4% -$10.7K 0.01% 538
2022
Q3 		$205K Buy
6,033
+2,116
+54% +$32.4K 0.01% 672
2022
Q2 		$37K Buy
+3,917
New +$40.8K ﹤0.01% 1396

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Parallel Advisors's AKRO Position: Q4 2025 in Review

Parallel Advisors sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 1,166 shares — an estimated $55.4K sold.

Parallel Advisors first reported a position in AKRO in Q2 2022 and held it in 14 quarters. The position peaked at $317K in Q4 2022. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Parallel Advisors reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Parallel Advisors sold 1,166 Akero Therapeutics shares in Q4 2025, an estimated $55.4K.
  • Parallel Advisors first reported a position in Akero Therapeutics in Q2 2022 and held it in 14 quarters.
  • Parallel Advisors's Akero Therapeutics position peaked at $317K in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Parallel Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.